Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer
Authors:
- Verónica Moncho-AmorVMVerónica Moncho-Amor
- Laura Pintado-BerninchesLPLaura Pintado-Berninches
- Inmaculada Ibañez de CáceresICInmaculada Ibañez de Cáceres
- Ester Martín-VillarEMEster Martín-Villar
- Miguel QuintanillaMQMiguel Quintanilla
- Probir ChakravartyPCProbir Chakravarty
- María Cortes-SempereMCMaría Cortes-Sempere
- Beatriz Fernández-VarasBFBeatriz Fernández-Varas
- Carlos Rodriguez-AntolínCRCarlos Rodriguez-Antolín
- Javier de CastroJCJavier de Castro
- Leandro SastreLSLeandro Sastre
- Rosario PeronaRPRosario Perona
Open Access
- 25 April 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (8) , 2036
Abstract
DUSP6/MKP3 is a dual-specific phosphatase that regulates extracellular regulated kinase ERK1/2 and ERK5 activity, with an increasingly recognized role as tumor suppressor. In silico studies from Gene expression Omnibus (GEO) and Cancer Genome atlas (TCGA) databases reveal poor prognosis in those Non-small cell lung cancer (NSCLC) patients with low expression levels of DUSP6. In agreement with these data, here we show that DUSP6 plays a major role in the regulation of cell migration, motility and tumor growth. We have found upregulation in the expression of several genes involved in epithelial to mesenchymal transition (EMT) in NSCLC-DUSP6 depleted cells. Data obtained in RNA-seq studies carried out in DUSP6 depleted cells identified EGFR, TGF-β and WNT signaling pathways and several genes such as VAV3, RUNXR2, LEF1, FGFR2 whose expression is upregulated in these cells and therefore affecting cellular functions such as integrin mediated cell adhesion, focal adhesion and motility. Furthermore, EGF signaling pathway is activated via ERK5 and not ERK1/2 and TGF-β via SMAD2/3 in DUSP6 depleted cells. In summary DUSP6 is a tumor suppressor in NSCLC and re-establishment of its expression may be a potential strategy to revert poor outcome in NSCLC patients.Keywords
Funding Information
- Instituto de Salud Carlos III (PI17-01401 and PI18/00050, PI-717 Miguel Servet)
- Ministerio de Ciencia e Innovación (SAF2017-84183-R)
This publication has 37 references indexed in Scilit:
- Tenascin-C Enhances Pancreatic Cancer Cell Growth and Motility and Affects Cell Adhesion through Activation of the Integrin PathwayPLOS ONE, 2011
- Snail2 is an Essential Mediator of Twist1-Induced Epithelial Mesenchymal Transition and MetastasisCancer Research, 2011
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- A History of Cancer ChemotherapyCancer Research, 2008
- ERK5 promotes Src-induced podosome formation by limiting Rho activationJournal of Cell Biology, 2008
- Dual-specificity MAP kinase phosphatases (MKPs) and cancerCancer and Metastasis Reviews, 2008
- Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the LungCancer Research, 2006
- Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeletonJournal of Cell Science, 2005
- Wavelet Thresholding with Bayesian False Discovery Rate ControlBiometrics, 2005
- Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCRNucleic Acids Research, 2002